Insys Therapeutics — Ethics Grade F

Insys Therapeutics receives an overall ethics grade of F (5/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Small Cap.

Category scores

• labor: 20
• privacy: 40
• consumer: 5
• environment: 50
• humanRights: 10

Documented incidents (3)

• Opioid Bribery Scheme (high, 2019) — Executives were convicted of racketeering for bribing doctors to prescribe Subsys, a powerful fentanyl spray, to patients who did not need it.
• Deceptive Marketing (high, 2018) — Internal company videos showed employees rapping and celebrating the high dosage sales of opioids, demonstrating a culture of profit over patient safety.
• Insurance Fraud (high, 2017) — Employees set up a call center to lie to insurance companies, pretending to be from doctor's offices to get Subsys prescriptions approved.

Documented good deeds

• Dronabinol Development — Developed Syndros to help AIDS and cancer patients with nausea and weight loss.

Ethical alternatives

• Vertex Pharmaceuticals — Strong focus on specialty medicine for cystic fibrosis with fewer marketing controversies.